The fibrinolytic system in the hemolytic uremic syndrome: in vivo and in vitro studies

Pediatr Res. 1994 Aug;36(2):257-64. doi: 10.1203/00006450-199408000-00019.

Abstract

Fibrinolytic parameters and von Willebrand factor (vWF) antigen were measured in the plasma of 10 patients with hemolytic uremic syndrome (HUS). Samples were taken at presentation and again 2 wk later, before and after infusion of 1-desamino-8-arginine vasopressin. Compared with the plasma values of healthy control children, levels of tissue-plasminogen activator (t-PA) antigen, plasminogen activator inhibitor type I (PAI-1) activity, and vWF as well as fibrin(ogen) degradation products were significantly elevated in the plasma of HUS patients on admission. No response of the fibrinolytic parameters and vWF were seen when 1-desamino-8-arginine vasopressin infusion was given on admission. After 2 wk, t-PA antigen and vWF had partially returned to basal values, and t-PA antigen increased rapidly again after 1-desamino-8-arginine vasopressin infusion. To investigate whether verocytotoxin contributes to the alteration of the fibrinolytic system found in HUS patients, purified verocytotoxin-1 (VT-1) was added to the media of cultured human endothelial cells. Addition of VT-1 alone did not change the production of t-PA, plasminogen activator inhibitor type I, and vWF antigen in these cells. However, when the endothelial cells were preincubated with tumor necrosis factor-alpha to increase the number of VT-1 receptors, VT-1 induced a marked decrease of the synthesis of t-PA, plasminogen activator inhibitor type I, and vWF. This was caused by a decrease in overall protein synthesis in the tumor necrosis factor-alpha- and VT-1-treated endothelial cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacterial Toxins / pharmacology
  • Cells, Cultured
  • Child, Preschool
  • Deamino Arginine Vasopressin / pharmacology
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / metabolism
  • Female
  • Fibrin Fibrinogen Degradation Products / metabolism
  • Fibrinolysis / drug effects
  • Fibrinolysis / physiology*
  • Hemolytic-Uremic Syndrome / blood*
  • Hemolytic-Uremic Syndrome / etiology
  • Humans
  • In Vitro Techniques
  • Infant
  • Male
  • Plasminogen Activator Inhibitor 1 / blood
  • Shiga Toxin 1
  • Tissue Plasminogen Activator / blood
  • Tumor Necrosis Factor-alpha / pharmacology
  • von Willebrand Factor / metabolism

Substances

  • Bacterial Toxins
  • Fibrin Fibrinogen Degradation Products
  • Plasminogen Activator Inhibitor 1
  • Shiga Toxin 1
  • Tumor Necrosis Factor-alpha
  • von Willebrand Factor
  • Tissue Plasminogen Activator
  • Deamino Arginine Vasopressin